Ultragenyx Pharmaceutical Inc (RARE)

Dec 21, 2024

Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 21, 2024

Dec 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 20, 2024

Dec 20, 2024

Ultragenyx Awards Key Employee Stock Grants: 15,175 RSUs Distributed in Strategic Talent Acquisition - StockTitan

Dec 20, 2024

Dec 20, 2024

RARE Submits BLA To The FDA For Sanfilippo Syndrome Gene Therapy - Barchart

Dec 20, 2024

Dec 20, 2024

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy - Zacks Investment Research

Dec 20, 2024

Dec 20, 2024

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $88.00 Price Target at Wells Fargo & Company - MarketBeat

Dec 20, 2024

Dec 20, 2024

Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts - Benzinga

Dec 20, 2024

Dec 20, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Geode Capital Management LLC - MarketBeat

Dec 20, 2024

Dec 20, 2024

Ultragenyx seeks FDA nod for Sanfilippo A gene therapy By Investing.com - Investing.com Canada

Dec 20, 2024

Dec 20, 2024

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire

Dec 20, 2024

Dec 19, 2024

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome - GlobeNewswire

Dec 19, 2024

Dec 19, 2024

Ultragenyx Launches Pivotal Phase 3 Trial for Breakthrough Angelman Syndrome Treatment GTX-102 - StockTitan

Dec 19, 2024

Dec 19, 2024

Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.

Dec 19, 2024

Dec 19, 2024

Ultragenyx seeks FDA nod for Sanfilippo A gene therapy - Investing.com

Dec 19, 2024

Dec 19, 2024

Ultragenyx Submits Biologics License Application to the - GlobeNewswire

Dec 19, 2024

Dec 19, 2024

Ultragenyx Seeks FDA Approval for Groundbreaking Sanfilippo Syndrome Gene Therapy - StockTitan

Dec 19, 2024

Dec 18, 2024

Ultragenyx Pharmaceutical Inc. Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) - Marketscreener.com

Dec 18, 2024

Dec 15, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 15, 2024

Dec 14, 2024

State Street Corp Has $147.99 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 14, 2024

Dec 13, 2024

Ultragenyx Pharmaceutical's SWOT analysis: rare disease biotech stock at crossroads - Investing.com

Dec 13, 2024

Dec 13, 2024

Y Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 13, 2024

Dec 13, 2024

Janus Henderson Group PLC Sells 35,200 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 13, 2024

Dec 11, 2024

Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion - The Globe and Mail

Dec 11, 2024

Dec 11, 2024

Hypophosphatasia Market Expected to Experience Major Growth - openPR

Dec 11, 2024

Dec 10, 2024

Frazier Life Sciences Management L.P. Purchases 208,715 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 10, 2024

Dec 09, 2024

CDKL5 Deficiency Disorder Pipeline 2024: Clinical Trials - openPR

Dec 09, 2024

Dec 09, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Wellington Management Group LLP - MarketBeat

Dec 09, 2024

Dec 09, 2024

BNP Paribas Financial Markets Sells 38,641 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 09, 2024

Dec 09, 2024

Opinion: What Accelerated Approval’s Naysayers Miss - BioSpace

Dec 09, 2024

Dec 07, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Jacobs Levy Equity Management Inc. - MarketBeat

Dec 07, 2024

Dec 06, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Point72 Asset Management L.P. - MarketBeat

Dec 06, 2024

Dec 06, 2024

Point72 DIFC Ltd Has $806,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 06, 2024

Dec 06, 2024

(RARE) On The My Stocks Page - Stock Traders Daily

Dec 06, 2024

Dec 05, 2024

Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Australia

Dec 05, 2024

Dec 05, 2024

RTW Investments LP Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 05, 2024

Dec 04, 2024

Possible Bearish Signals With Ultragenyx Pharmaceutical Insiders Disposing Stock - Simply Wall St

Dec 04, 2024

Dec 04, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Lessened by Cinctive Capital Management LP - MarketBeat

Dec 04, 2024

Dec 04, 2024

Bamco Inc. NY Purchases New Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 04, 2024

Dec 04, 2024

Erste Asset Management GmbH Makes New Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 04, 2024

Dec 04, 2024

Verition Fund Management LLC Reduces Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 04, 2024

Dec 04, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat

Dec 04, 2024

Dec 03, 2024

Cerity Partners LLC Invests $1.77 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 03, 2024

Dec 02, 2024

Baker BROS. Advisors LP Has $87.55 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Dec 02, 2024

Nov 29, 2024

Capstone Investment Advisors LLC Purchases Shares of 13,089 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 29, 2024

Nov 29, 2024

Vestal Point Capital LP Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 29, 2024

Nov 29, 2024

Suvretta Capital Management LLC Sells 910,112 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 29, 2024

Nov 29, 2024

Alkeon Capital Management LLC Boosts Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 29, 2024

Nov 28, 2024

Acuta Capital Partners LLC Purchases New Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 28, 2024

Nov 27, 2024

Ultragenyx to Participate in Investor Conferences in December - GlobeNewswire

Nov 27, 2024

Nov 26, 2024

Ultragenyx to Present at Three Major Healthcare Investor Conferences in December | RARE Stock News - StockTitan

Nov 26, 2024

Nov 26, 2024

CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail

Nov 26, 2024

Nov 26, 2024

CDKL5 Deficiency Disorder Market Revenue to Expand - openPR

Nov 26, 2024

Nov 26, 2024

Algert Global LLC Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 26, 2024

Nov 26, 2024

Massachusetts Financial Services Co. MA Purchases 172,126 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 26, 2024

Nov 26, 2024

Swiss National Bank Grows Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 26, 2024

Nov 25, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Boosted by Natixis Advisors LLC - MarketBeat

Nov 25, 2024

Nov 24, 2024

Connor Clark & Lunn Investment Management Ltd. Sells 87,626 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 24, 2024

Nov 23, 2024

Top 10 startups in Rare Diseases in Bay Area, United States in Nov, 2024 - Tracxn

Nov 23, 2024

Nov 23, 2024

B. Metzler seel. Sohn & Co. Holding AG Takes $1.32 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 23, 2024